
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. demonstrates strong potential for growth due to its innovative DDX gene delivery platform, which allows for localized delivery of gene therapies to mucosal tissues and other organs. The company has received RMAT designation for detalimogene, positioning it to capture substantial market share, especially in community practice settings, enhanced by promising clinical results and a competitive efficacy profile compared to best-in-class assets. Additionally, the increase in research and development expenses reflects a commitment to advancing its pivotal LEGEND study, further substantiating a positive outlook for future performance and valuation metrics.
Bears say
enGene Holdings Inc faces significant challenges that negatively impact its outlook. The ongoing LEGEND trial has shown disappointing results for Detalimogene, with emerging safety concerns and changing regulatory requirements that may hinder approval timelines. Additionally, the company is at risk of increased capital requirements leading to equity dilution, compounded by heightened competitive pressures in the biotechnology space where larger, more established firms dominate.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares